MedDay raises $38.5M to kick off U.S. clinical trials for multiple sclerosis
MedDay's new spate of U.S. trials follow the successful Phase 3 study in progressive multiple sclerosis in Europe.
Broad Institute partners with Amazon, Google, IBM to bring genome analysis software to the cloud
The Broad Institute plans to develop and roll out GATK4, the next generation version of Genome Analysis Toolkit. The new service will include cancer, structural variation, copy number variation and related functionality.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Lumos Pharma raises $34M to treat inherited autism-like disorder
The round, led by Deerfield Management, will support clinical development of a drug for creatine transporter deficiency.
Pfizer backs out of $160B Allergan deal; White House scores victory
Pfizer's backed out of that historic $160 billion merger with Allergan, thanks to Washington toughening up on corporate inversions.
Infographic: Why does JAMA say insulin has tripled in price?
It's worthwhile to resurrect a 2015 infographic from the Alliance of Community Health Plans that shows which insulin analogs are spiking most in price.
Morning Read: Valeant slashes sales staff for women’s libido pill Addyi
Also, Gilead made a deal worth up to $1.2 billion to acquire drugs that treat NASH and liver cancer.
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
J. Craig Venter’s Human Longevity nabs $220M to expand Health Nucleus
The funding will be used to build out Health Nucleus, HLI's clinical research center, and expand its database of whole genome, phenotype and clinical data.
Peter Thiel firm Mithril Capital Management raises $600M
Sources say the Peter Thiel-backed firm is oversubscribed for this fund, and it may reach $1 billion before it closes.
Is the time right for digital therapeutics? 5 must-read stories from MedCity News this week
Every week, we compile the most trafficked and thoughtful stories on MedCity News. Most influential: Whether there's enough caregiving manpower available to meet the demand.
Gotcha! The top five April Fool’s Day pranks in healthcare
Of course, ZDoggMD makes this list with a hilarious video promoting the anti-vaccination movement. Also, April Fool's pranks from CosmosID and Twine Health.
Maximize Revenue and Patient Care with Strategic Weight Loss Management
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Theranos failed internal quality control measures, government report says
Furthermore, Edison tests were run by unqualified personnel - and there were often lengthy delays in Theranos telling patients that their test results were flawed, or that or that blood samples were stored at the wrong temperature.
FTC sues Endo Pharmaceuticals for paying off generic drugmakers – and delaying market entry
The Federal Trade Commission has sued Endo Pharmaceuticals and several other drugmakers, saying they've entered "pay-for-delay" deals that postpone generic versions of its drugs to hit the market.
Nestlé Health Science expanding biotech investment
Nestlé is expanding its tentacles from chocolatier into drug development – investing in companies focused on microbiota, muscle loss and Alzheimer’s disease. STAT talked with Greg Behar, CEO of the new Nestlé Health Science subsidiary of the company, on the company’s foray into the life sciences. The company’s health science subsidiary was launched five years ago, and employs […]
Centrexion nabs three non-opioid pain drugs from Boehringer Ingelheim
Boehringer Ingelheim offloaded the drugs, it said in a statement. because it's shifting away from pain medications to focus on CNS diseases like Alzheimer's, schizophrenia and depression.
Zavante raises $45M to bring antibiotic fosfomycin to U.S.
So why is Zavante brushing the dust off fosfomycin? After all, it was actually first tested in the 1960s in Spain, but had been ruled as fairly ineffective in comparison to other antibiotics on the market.